SELECTIVE AKT INHIBITORS SYNERGIZE WITH TYROSINE KINASE INHIBITORS AND EFFECTIVELY OVERRIDE STROMA-ASSOCIATED CYTOPROTECTION OF MUTANT FLT3-POSITIVE AML CELLS.